IF1 attenuated HCC cell sensitivity to sorafenib therapy after insufficient RFA through NF-κB signaling and indicated poor disease free survival in patients with HCC after sorafenib treatment. Here, ATP5IF1 is linked to hepatocellular carcinoma.